These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 37286302)

  • 1. Vaccinating against cancer: getting to prime time.
    Chang R; Gulley JL; Fong L
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37286302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral Immunotherapy-Update 2019.
    Hamid O; Ismail R; Puzanov I
    Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.
    Dummer R; Hoeller C; Gruter IP; Michielin O
    Cancer Immunol Immunother; 2017 Jun; 66(6):683-695. PubMed ID: 28238174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
    Cavalcante L; Chowdhary A; Sosman JA; Chandra S
    Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic viruses as engineering platforms for combination immunotherapy.
    Twumasi-Boateng K; Pettigrew JL; Kwok YYE; Bell JC; Nelson BH
    Nat Rev Cancer; 2018 Jul; 18(7):419-432. PubMed ID: 29695749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic virus immunotherapy for melanoma.
    Dharmadhikari N; Mehnert JM; Kaufman HL
    Curr Treat Options Oncol; 2015 Mar; 16(3):326. PubMed ID: 25777572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
    Gangi A; Zager JS
    Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
    Kohlhapp FJ; Kaufman HL
    Clin Cancer Res; 2016 Mar; 22(5):1048-54. PubMed ID: 26719429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety.
    Raman SS; Hecht JR; Chan E
    Immunotherapy; 2019 Jun; 11(8):705-723. PubMed ID: 31045464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Oncolytic Viruses in the Treatment of Melanoma.
    Bayan CY; Lopez AT; Gartrell RD; Komatsubara KM; Bogardus M; Rao N; Chen C; Hart TD; Enzler T; Rizk EM; Pradhan JS; Marks DK; Geskin LJ; Saenger YM
    Curr Oncol Rep; 2018 Aug; 20(10):80. PubMed ID: 30145781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
    Shi T; Song X; Wang Y; Liu F; Wei J
    Front Immunol; 2020; 11():683. PubMed ID: 32411132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
    Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
    Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.
    Chesney J; Imbert-Fernandez Y; Telang S; Baum M; Ranjan S; Fraig M; Batty N
    Melanoma Res; 2018 Jun; 28(3):250-255. PubMed ID: 29561296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Talimogene laherparepvec: First in class oncolytic virotherapy.
    Conry RM; Westbrook B; McKee S; Norwood TG
    Hum Vaccin Immunother; 2018 Apr; 14(4):839-846. PubMed ID: 29420123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic Viruses in Cancer Treatment: A Review.
    Lawler SE; Speranza MC; Cho CF; Chiocca EA
    JAMA Oncol; 2017 Jun; 3(6):841-849. PubMed ID: 27441411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
    Kohlhapp FJ; Zloza A; Kaufman HL
    Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.
    Garnock-Jones KP
    BioDrugs; 2016 Oct; 30(5):461-468. PubMed ID: 27516203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma.
    Hoffner B; Iodice GM; Gasal E
    Oncol Nurs Forum; 2016 Mar; 43(2):219-26. PubMed ID: 26906132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
    Ribas A; Dummer R; Puzanov I; VanderWalde A; Andtbacka RHI; Michielin O; Olszanski AJ; Malvehy J; Cebon J; Fernandez E; Kirkwood JM; Gajewski TF; Chen L; Gorski KS; Anderson AA; Diede SJ; Lassman ME; Gansert J; Hodi FS; Long GV
    Cell; 2017 Sep; 170(6):1109-1119.e10. PubMed ID: 28886381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
    Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
    J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.